• Canbridge Pharmaceuticals held its annual general meeting on June 23, 2026.
• Shareholders adopted the audited consolidated financial statements and related directors’ and auditor’s reports for the year ended Dec. 31, 2025.
• Director reappointments were endorsed, excluding any reference to an election process.
• HLB Hodgson Impey Cheng Limited was reappointed as auditor; the board was authorized to set the auditor’s remuneration.
• Mandates to issue new shares, repurchase shares, extend the issuance mandate by shares repurchased, and grant share options and RSUs to James Qun Xue were approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260623-12211481), on June 23, 2026, and is solely responsible for the information contained therein.